Transgene Raises €105 Million for Cancer Vaccine Development

Transgene, a biotechnology company developing viral vector-based immunotherapies for cancer treatment, announced the successful completion of a €105 million fundraising. The capital was raised through a private placement with institutional investors and a public offering on the PrimaryBid platform.

The funds will accelerate the development of Transgene's myvac® platform, focused on individualized therapeutic cancer vaccines, extending financial visibility until early 2028. The proceeds will primarily support ongoing and upcoming trials in head and neck cancer, alongside general corporate purposes.

Key investors include Institut Mérieux's TSGH and the Dassault Group, with significant subscription levels reflecting strong confidence in Transgene's strategic vision.